论文部分内容阅读
目的探讨卡培他滨在晚期乳腺癌维持治疗中的疗效及安全性。方法 56例晚期乳腺癌患者,均为经一线含卡培他滨联合化疗4~6周期达缓解或稳定者,依据治疗方法不同分为治疗组与对照组,卡培他滨维持治疗组(35例)患者给予卡培他滨口服1000 mg/m2日2次,d1~14,21 d为1个周期,对照组(21例)患者予以定期随访观察。比较两组患者无进展生存率(PFS)、总生存率(OS)与安全性。结果卡培他滨维持治疗组PFS为8.6个月,高于对照组的6.2个月,差异有统计学意义(P<0.05)。治疗组OS为23.2个月,高于对照组的15.7个月,差异有统计学意义(P<0.05)。卡培他滨治疗组总有效率RR为17.1%(6/35),疾病控制率DCR为68.6%(24/35)。主要不良反应为手足综合征、骨髓抑制及胃肠道反应,均可控制。结论卡培他滨作为晚期乳腺癌一线联合化疗后的维持治疗用药,可延长患者生存期,不良反应可耐受,依从性好。
Objective To investigate the efficacy and safety of capecitabine in the maintenance treatment of advanced breast cancer. Methods 56 patients with advanced breast cancer were all remission or stabilization after the first-line treatment with capecitabine combined with 4 to 6 cycles of chemotherapy. According to different treatment methods, they were divided into treatment group and control group, and capecitabine maintenance treatment group (35 Example: Patients were given capecitabine orally 1000 mg/m 2 twice a day for 1 to 14 and 21 days. Patients in the control group (21 patients) were observed at regular intervals. The progression-free survival (PFS), overall survival (OS), and safety were compared between the two groups. Results The PFS in capecitabine maintenance group was 8.6 months, which was higher than the 6.2 months in the control group. The difference was statistically significant (P<0.05). The OS of the treatment group was 23.2 months, which was higher than the 15.7 months of the control group. The difference was statistically significant (P<0.05). The total effective RR was 17.1% (6/35) in the capecitabine treatment group, and the disease control rate DCR was 68.6% (24/35). The main adverse reactions were hand-foot syndrome, myelosuppression and gastrointestinal reactions, which could all be controlled. Conclusions Capecitabine is a maintenance therapy for patients with advanced breast cancer after first-line chemotherapy. It can prolong the survival of patients, and the adverse reactions can be tolerated and the compliance is good.